TB-500 Overdose and Accidental Excess Dose: Recognition, Risks, and Clinical Management

The Most Important Fact: Human Overdose Data Are Missing

TB-500 is a name used for an unapproved peptide product. FDA explains that unapproved drugs have not been reviewed for safety, effectiveness, or quality. TB-500 is often described online as a fragment related to thymosin beta-4, but product names, sequences, concentrations, and manufacturing quality may not be consistent across sellers. That makes a suspected “overdose” different from taking an extra tablet of an FDA-approved medicine with a verified ingredient and strength.

The FDA has specifically evaluated a thymosin beta-4 fragment described as LKKTETQ, often associated with the name TB-500, in its review of bulk substances that may present significant safety risks in compounding. FDA states that the fragment may pose an immunogenicity risk and that peptide-related impurities may also stimulate an immune response. The agency also says it identified no human exposure data for drug products containing this fragment and lacks important information about whether it would cause harm in humans. See FDA’s current page, Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks.

Those statements do not establish that every exposure will cause injury. They mean there is not a sound evidence base for reassuring someone that a particular amount is safe, predicting a clearance time, or assigning a home-observation window.

Why Online “Safe Dose” Claims Are Unreliable

Claims about a standard TB-500 loading phase, maintenance schedule, half-life, lethal dose, or large “safety margin” are not established by an FDA-approved label. Research involving full-length thymosin beta-4, a different sequence, a topical formulation, an animal model, or a controlled investigational product cannot verify what is inside an internet-purchased vial or predict its toxicity.

Several uncertainties matter at once:

• Identity: the vial may contain a different peptide, an incomplete sequence, or no active peptide.
• Potency: the actual amount can differ from the labeled amount.
• Reconstitution: a calculation, unit, syringe, or diluent error can change the delivered concentration.
• Sterility: an injectable can introduce bacteria, fungi, or endotoxin.
• Impurities: peptide synthesis and degradation can produce related compounds with unknown effects.
• Co-exposures: other medicines, peptides, alcohol, or drugs can change the clinical picture.

For these reasons, a report such as “I injected twice the intended units” is useful, but it is not enough to calculate risk from a universal formula.

What to Do After a Suspected Excess Dose

1. Stop using the product

Do not take another dose to “balance” the schedule and do not inject anything else into the same site. Do not induce vomiting after an injection or oral exposure unless Poison Control specifically instructs you to do so.

2. Call the right service

In the United States, call Poison Control at 1-800-222-1222 or use the official Poison Control assistance page. The service can assess the substance, route, time, symptoms, age, health conditions, and other medicines. Advice is individualized; a web article cannot substitute for that real-time assessment.

Call 911 immediately if the person collapses, has a seizure, has trouble breathing, or cannot be awakened. Do not wait for an online reply or drive an unstable person without emergency guidance.

3. Preserve the evidence

Keep the vial, box, syringe, receipt, seller or pharmacy information, lot number, and any reconstitution instructions. Photograph the front and back of the label. If possible, write down:

• the exact product name as printed;
• the labeled amount and concentration;
• how much diluent was added;
• the syringe type and marking used;
• the estimated amount administered;
• the time and route of exposure;
• current symptoms; and
• all other medicines or substances used that day.

Do not discard or mail the product while urgent medical decisions are being made. Clinicians or public-health authorities may need identifying details.

4. Follow symptom-based instructions

Poison Control or an emergency clinician may advise observation, evaluation, or emergency transport depending on the facts. The official Poison Control assistance page also explains when to call 911. There is no validated TB-500 protocol requiring blood pressure checks every 15 minutes, a fixed two-hour window, or automatic clearance after several estimated half-lives. A person can also be injured by contamination or an allergic response that is not explained by peptide pharmacokinetics.

Symptoms That Need Urgent Attention

Because the human toxicity profile is undefined, assessment should not be limited to a short list of expected adverse effects. Seek urgent medical help for:

• trouble breathing, wheezing, throat tightness, facial or tongue swelling, or widespread hives;
• collapse, fainting, seizure, confusion, unusual drowsiness, or inability to awaken;
• chest pain, severe weakness, a very fast or irregular heartbeat, or blue/gray lips;
• repeated vomiting, severe abdominal pain, or inability to keep fluids down;
• rapidly expanding redness, severe pain, warmth, drainage, streaking, or swelling at an injection site;
• fever or shaking chills after an injection; or
• any rapidly worsening or frightening symptom.

An injection-site infection may appear later rather than immediately. Increasing redness, pain, warmth, pus, fever, or systemic illness after an unapproved injection warrants medical assessment even if the original dosing error seemed minor.

What Emergency Evaluation May Involve

There is no TB-500-specific antidote or evidence-based laboratory panel. Emergency care is guided by symptoms and the uncertainty of the product. Clinicians may assess airway, breathing, circulation, mental status, skin findings, the injection site, hydration, and heart rhythm. Tests are selected for the presentation rather than ordered from a universal peptide checklist.

Bring the product information and explain exactly what happened without assuming the label is accurate. Terms such as “thymosin beta-4,” “TB-500,” and “thymosin beta-4 fragment” may refer to different material. This distinction can help a poison specialist search the right information.

Supportive treatment may be used for problems such as an allergic reaction, abnormal vital signs, dehydration, infection, or complications from a co-exposure. That does not validate the underlying product or establish that future use is safe.

Compounding and Unapproved-Product Risk

FDA-approved drugs undergo premarket review for safety, effectiveness, quality, and labeling. Compounded drugs are not FDA-approved, and FDA explains that unnecessary use can expose patients to products that may be contaminated or contain too much or too little active ingredient. See Compounding and FDA: Questions and Answers.

It is also unsafe to assume that any online source calling itself a “compounding pharmacy” dispensed a lawful, patient-specific prescription. Product provenance should be verified by clinicians and regulators, not inferred from branding or a certificate posted by the seller.

If a clinician believes the product caused a serious adverse event or product-quality problem, FDA’s MedWatch program provides reporting routes. Reporting is not a replacement for emergency care.

Preventing Another Dosing Error

The safest prevention is not to use an unapproved product with uncertain human safety. FDA's compounding questions and answers explain that compounded drugs are not FDA-approved. If a person has already received a product through a healthcare setting, the prescriber and dispensing pharmacy should review the exact prescription and product before any further use.

Do not rely on a generic internet reconstitution recipe. Milligrams, micrograms, milliliters, and syringe “units” are not interchangeable. The marking on a syringe is a volume designation for that syringe, not proof of how many milligrams of peptide it contains. Concentration depends on both the verified amount in the vial and the verified volume added.

After any error, request a plain-language written plan that states the product, concentration, dose in mass and volume, syringe type, route, and what to do if a dose is missed. If those facts cannot be verified, further administration cannot be made safe by a calculator.

What This Page Cannot Promise

No reliable evidence supports a claim that a doubled TB-500 dose is “unlikely to be life-threatening,” that a person is safe after a fixed number of hours, or that animal toxicology creates a human safety margin. FDA's TB-500 fragment risk summary instead documents missing human exposure data. The lack of published fatal cases is not proof of safety; incomplete surveillance is expected for unapproved products.

The evidence-supported conclusion is narrower: the human risk is insufficiently characterized, FDA has identified specific immunogenicity and impurity concerns, and a suspected exposure should be handled with Poison Control or emergency services according to the person’s symptoms and circumstances.